Cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic hematopoietic stem cell transplantation: viremia, immunogenicity and survival outcomes in a randomised phase 1b trial

BACKGROUND: Cytomegalovirus (CMV) seropositive recipients of allogeneic hematopoietic cell transplantation (HCT) are at risk for CMV reactivation. Stimulating viral immunity by vaccination may achieve CMV viremia control, without the need for antivirals. The aim of the trial is to assess safety, imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Ryotaro, La Rosa, Corinna, Longmate, Jeffrey, Drake, Jennifer, Slape, Cynthia, Zhou, Qiao, Lampa, Melanie G., O'Donnell, Margaret, Cai, Ji-Lian, Farol, Len, Salhotra, Amandeep, Snyder, David S., Aldoss, Ibrahim, Forman, Stephen J., Miller, Jeffrey S., Zaia, John A., Diamond, Don J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926626/
https://www.ncbi.nlm.nih.gov/pubmed/26853648
http://dx.doi.org/10.1016/S2352-3026(15)00246-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926626/
https://www.ncbi.nlm.nih.gov/pubmed/26853648
http://dx.doi.org/10.1016/S2352-3026(15)00246-X

Ejemplares similares